ArticleBMC medical informatics and decision making2025
Optimizing unsupervised feature engineering and classification pipelines for differentiated thyroid cancer recurrence prediction.
Article in BMC medical informatics and decision making, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and validation of an interpretable machine learning model for postoperative radiotherapy decision-making in ypN0 breast cancer after neoadjuvant chemotherapy: a real-world study.BMC medical informatics and decision making · 2026Article
- CatBoost with physics-based metaheuristics for thyroid cancer recurrence prediction.BioData mining · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifferentiated thyroid cancer (DTC) is a common endocrine malignancy with rising incidence and frequent recurrence, despite a generally favorable prognosis. Accurate recurrence prediction is critical for guiding post-treatment strategies. This study aimed to enhance predictive performance by refining feature engineering and evaluating a diverse ensemble of machine learning models using the UCI DTC dataset.
methodsUnsupervised data engineering-specifically dimensionality reduction and clustering-was used to improve feature quality. Principal Component Analysis (PCA) and Truncated Singular Value Decomposition (t-SVD) were selected based on superior clustering metrics: adjusted Rand Index (ARI > 0.55) and V-measure (> 0.45). These were integrated into classification pipelines using Logistic Regression (LR), Support Vector Machine (SVM), Random Forest (RF), K-Nearest Neighbors (KNN), Feedforward Neural Network (FNN), and Gradient Boosting (GB). Model performance was evaluated through bootstrapping on an independent test set, stratified 10-fold cross-validation (CV), and subgroup analyses. Metrics included balanced accuracy, F1 score, AUC, sensitivity, specificity, and precision, each reported with 95% confidence intervals (CIs). SHAP analysis supported model interpretability.
resultsThe PCA-based LR pipeline achieved the best test set performance: balanced accuracy of 0.95 (95% CI: 0.90-0.99), AUC of 0.99 (95% CI: 0.97-1.00), and sensitivity of 0.94 (95% CI: 0.84-1.00). In stratified CV, it maintained strong results (balanced accuracy: 0.86; AUC: 0.97; sensitivity: 0.80), with consistent performance across clinically relevant subgroups. The t-SVD-based LR pipeline showed comparable performance on both test and CV sets. SVM and FNN pipelines also performed robustly (test AUCs > 0.99; CV AUCs > 0.96). RF and KNN had high specificity but slightly lower sensitivity (test: ~0.87; CV: 0.77-0.80). GB pipelines showed the lowest overall performance (test balanced accuracy: 0.86-0.88; CV: 0.85-0.88).
conclusionsDimensionality reduction via PCA and t-SVD significantly improved model performance, particularly for LR, SVM, FNN, RF and KNN classifiers. The PCA-based LR pipeline showed the best generalizability, supporting its potential integration into clinical decision-support tools for personalized DTC management. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.